Max Healthcare lifts operating margin, but shares fall 6.22%
Revenue outpaced expenses YoY, but higher tax and financing costs limited net-profit growth to 7.28%.
Filed 21 May 2026, 16:25 IST · after market close · Max Healthcare Institute Ltd (MAXHEALTH)
Key takeaways
- Consolidated operating margin widened 1.51 percentage points YoY to 28.30% as revenue growth outpaced expense growth.
- Net profit rose only 7.28% YoY as the tax rate increased 5.59 percentage points and interest expense rose 20.74%.
- The stock fell 6.22% on the first reaction day, well beyond its 1.84% median absolute move after the last eight results.
Price around the results
Q4 margin recovery drives operating profit
Max Healthcare’s consolidated revenue grew +12.21% YoY while expenses grew +9.89%, allowing operating profit to rise +18.53% and operating margin to widen 1.51 percentage points. Sequentially, revenue grew +3.65% against expense growth of +0.48%, lifting margin by 2.26 percentage points from Q3FY26. The 28.30% margin was 4.92 percentage points above the 23.38% median across 48 healthcare peers that had reported.
Tax and financing costs dilute operating gains
Interest expense increased +20.74% YoY and depreciation rose +22.01%, while the tax rate increased 5.59 percentage points to 26.34%. That cost and tax drag meant net profit grew only +7.28%, well below operating-profit growth. Other income contributed 10.30% of pre-tax profit, so reported earnings also included a meaningful non-operating component.
Capacity additions remain central to the company’s plans
Management said FY26 delivered profitable growth despite the addition of new capacities. The company said it expects to add around 4,000 beds over the next three to four years, including around 2,000 beds through brownfield expansion. Management also said it has potential to expand capacity by more than 8,400 beds through FY30 and beyond, with acquired land parcels supporting around 1,000 beds in Gurgaon and 550 beds in Lucknow.
The market reaction was unusually negative
The stock fell 6.22% on the first reaction day and was down 13.99% by day five, compared with a median absolute post-result move of 1.84% across the last eight results. That is out of line with the stock’s recent pattern, where six of eight result reactions were positive. The reaction period overlapped with a corporate action, which is an additional factor when interpreting the move.
Q4FY26 at a glance
Consolidated figures as filed with NSE — cross-checked against an independent source.
| Line item | Q4FY26 | Q3FY26 | QoQ | YoY |
|---|---|---|---|---|
| Revenue | ₹2,143 cr | ₹2,068 cr | +3.65% | +12.21% |
| Other income | ₹48 cr | ₹-3 cr | — | +1.94% |
| Expenses | ₹1,536 cr | ₹1,529 cr | +0.48% | +9.89% |
| Operating profit | ₹606 cr | ₹538 cr | +12.65% | +18.53% |
| Operating margin (%) | 28.30% | 26.04% | — | — |
| Interest | ₹67 cr | ₹60 cr | +11.71% | +20.74% |
| Depreciation | ₹123 cr | ₹111 cr | +10.56% | +22.01% |
| Profit before tax | ₹465 cr | ₹365 cr | +27.44% | +15.42% |
| Tax | ₹122 cr | ₹64 cr | +92.33% | +46.54% |
| Net profit | ₹342 cr | ₹301 cr | +13.72% | +7.28% |
| EPS (₹) | ₹3.52 | ₹3.10 | +13.55% | +7.32% |
Operating margin of 28.30% compares with a Healthcare sector median of 23.38% across 48 peers that have reported Q4FY26.
How the stock reacted
| Window | Stock | vs NIFTY |
|---|---|---|
| Results day | -6.22% | -6.49% |
| Next session | -8.27% | — |
| 5 sessions | -13.99% | -12.84% |
| 15 sessions | -5.70% | — |
| 30 sessions | +2.50% | — |
Volume on the results session was 6.44× its 20-day average.
What management said
From the company’s own investor presentation. Each point is checked against the source document before it appears here.
This quarter
- The company reported profitable growth and steady performance in FY26 despite adding new capacities.
Guidance & outlook
- The company expects to add around 4,000 beds in the next three to four years.
- The company targets ROCE of 20-25% within four years after an acquisition.
- The company expects acquired land parcels to support around 1,000 beds in Gurgaon and 550 beds in Lucknow.
Expansion
- Around 2,000 beds are planned through brownfield expansion.
- The company has potential to expand capacity by more than 8,400 beds through FY30 and beyond.
Competition
- The company states that limited competitive intensity and a robust deal pipeline support future growth.
- Max Healthcare has more than 4,400 beds in metropolitan areas.
What to watch
- Whether operating margin holds above 28.30% after its 2.26-percentage-point sequential recovery.
- Whether expense growth remains below revenue growth after +9.89% versus +12.21% YoY in Q4FY26.
- Progress on management’s stated plan to add around 4,000 beds over the next three to four years.